Clinico-epidemiological profile and treatment outcome of pituitary adenomas: a retrospective study

Tavseef Ahmad Tali; Fiza Amin; Shahid Rashid Sofi; Nazir Ahmad Khan; Javaid Ahmad Dar; Mushtaq Ahmad Sofi

doi:10.18203/2320-6012.ijrms20231639

Authors

Tavseef Ahmad Tali Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Fiza Amin Department of Gynaecology and Obstetrics, Skims Medical College and Hospital, Srinagar, Jammu and Kashmir, India
Shahid Rashid Sofi Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Nazir Ahmad Khan Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Javaid Ahmad Dar Department of Cardiology, Christian Medical College, Vellore, Tamil Nadu, India
Mushtaq Ahmad Sofi Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231639

Keywords:

Epidemiology, Overall survival, Pituitary adenoma, Radiotherapy

Abstract

Background: Aim of this study was to evaluate the clinico-epidemiological profile and treatment outcome of pituitary adenomas.

Methods: This was a retrospective study performed in the department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, India, in which 30 cases diagnosed with pituitary adenoma from January 2016 to December 2021 were studied. There clinical and epidemiological features, treatment, overall survival and follow-up data was analyzed.

Results: Most patients were female in gender 17 (57%), and the incidence rate was higher in female patients than male. Microadenoma was seen in just 4 (13%) patients. Macroadenoma in 12 (40%) and giant tumours in 14 (47%). At three and five years, the overall survival rate was 92% and 83%, respectively. Additionally, patients who got adjuvant radiation had a higher overall survival rate (84% versus 76%, p=.833) than those who did not.

Conclusions: Radiotherapy is an effective treatment for pituitary adenomas, able to achieve excellent disease control. Patients with pituitary adenomas should be identified at an early stage so that effective treatment can be implemented. Initial therapy is generally transsphenoidal surgery with irradiation reserved for patients who do not achieve adequate reduction in tumor size after surgery.

Metrics

Metrics Loading ...

References

Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, et al. The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2010;24(3):461-76.

Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516-24.

Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613-9.

Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655-64.

Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM. Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894-904.

Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med. 2020;382(10):937-50.

Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab. 2012;97(4):1073-81.

Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic vs microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psych. 2013;84(8):843-9.

Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery. Neurosurg. 1997;40(2):225-36.

Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000.J Clin Endocrinol Metab. 2003;88(10):4709-4719.

Cote DJ, Alzarea A, Acosta MA, Hulou MM, Huang KT, Almutairi H, et al. Predictors and rates of delayed symptomatic hyponatremia after transsphenoidal surgery: a systemastic review. World Neurosurg. 2016;88:1-6.

Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7:1992-2003.

Ding D, Starke RM, Sheehan JP. Treatment paradigms for pituitary adenomas. J Neurooncol. 2014;117(3):445-57.

Gupta T, Chatterjee A. Modern radiation therapy for pituitary adenoma: review of techniques and outcomes. Neurol India. 2020;68(Suppl S1):113-2.

Katznelson L, Laws Jr ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.

Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-31.

Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S. French Endocrinology Society non-functioning pituitary adenoma work-group. Management of clinically nonfunctioning pituitary adenoma. Ann Endocrinol (Paris). 2015;76(3):239-47.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The J Clin Endocrinol Metabol. 2011;96(2):273-88.

Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545-53.

Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metabol. 2010;95(9):4268-75.

Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, et al.. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014;171(4):519-26.

Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37(1):67-73.

Tardivo V, Penner F, Garbossa D, Di Perna G, Pacca P, Salvati L, et al. Surgical management of pituitary adenomas: does age matter? Pituitary. 2020;23(2):92-102.

Lobatto DJ, de Vries F, Zamanipoor Najafabadi AH, Pereira AM, Peul WC, Vliet Vlieland TP, et al. Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. Pituitary. 2018;21(1):84-97.

Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in Stokeon-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 2011;96(3):632-42.

Nilsson B, Gustavsson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: Incidence, survival, and mortality. J. Clin. Endocrinol. Metab. 2000;85(4):1420-5.

Ntali G, Capatina C, Fazal-Sanderson V, Byrne JV, Cudlip S, Grossman AB, et al. Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol. 2016;174(2):137-45.

Javanmard P, Duan D, Geer EB. Mortality in patients with endogenous Cushing’s syndrome. Endocrinol Metabol Clin. 2018;47(2):313-33.

Chen C, Hu Y, Lyu L, Yin S, Yu Y, Jiang S, et al. Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004–2016. Sci Rep. 2021;11(1):1-9.